北京先通国际医药科技有限公司 is a biotechnology and pharmaceutical company based in Beijing, founded in 2005. Over the past 11 years, the company has evolved from a drug research CRO company to a comprehensive medical industry group that encompasses research and development, drug production, sales, import-export trade of pharmaceuticals, and international cooperation. With a registered capital of CNY300 million, the company has stakes in and controlling interests in numerous pharmaceutical and medical companies domestically and internationally.
In the coming years, the company aims to transition from a primarily generic drug-focused traditional pharmaceutical enterprise to a new medical entity centered around integrating high-quality resources both domestically and internationally, utilizing nuclear medicine technology as a platform, with precision diagnosis and treatment as the direction, and innovative drugs as the core.
北京先通达生物医药技术有限公司 is a high-tech biotechnology research and development platform under 先通医药集团. Its research focuses on oncology drugs, Alzheimer's and cardiovascular drugs. It integrates research technologies with advanced resources domestically and internationally, collaborating with a U.S. monoclonal antibody drug research lab and achieving a series of research results at the forefront of the world. Simultaneously, the company actively engages in academic collaboration with institutions such as Harvard University's medical school, actively cultivating research and development varieties as a foundation for its future development.
The company's most recent investment round was a CNY1.10B Series E investment on 03 July 2023. The investors included GF Qianhe Investment, China Life Equity, China Structural Reform Fund, Wuxi Venture Capital Group, GoldStone Investment, EasyDiagnosis, Stone Capital, Enran Chuangtou, Jimin Touzi, Zhongshan Qingqi Chuangtou.
